Literature DB >> 35836082

Applications of Bioluminescence-Optogenetics in Rodent Models.

Matthew A Stern1, Henry Skelton1, Alejandra M Fernandez1, Claire-Anne N Gutekunst1, Robert E Gross1, Ken Berglund2.   

Abstract

In the preceding chapter, we introduced bioluminescence-optogenetics (BL-OG) and luminopsin fusion proteins (LMOs), an emerging method of molecular neuromodulation. In addition to reviewing the fundamental principles of BL-OG, we provided a discussion of its application in vitro, including with cell lines and primary cells in culture in vitro. BL-OG is mediated by an easily diffusible molecule, luciferin, and when applied systemically in rodents, the substrate can spread throughout the body, including the brain, achieving powerful molecular neuromodulation with convenience even in awake and behaving animals. In this chapter, we provide a practical guide for BL-OG and LMO applications in rodent models of the nervous system, both ex vivo and in vivo.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anesthetized; Awake; BLI; Bioluminescence (BL); Coelenterazine (CTZ); Electrophysiology; Luciferase; Luciferin; Luminopsins (LMOs); Mice; Rats

Mesh:

Substances:

Year:  2022        PMID: 35836082     DOI: 10.1007/978-1-0716-2473-9_27

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Motoneuron activity is required for enhancements in functional recovery after peripheral nerve injury in exercised female mice.

Authors:  Poonam B Jaiswal; Jack K Tung; Robert E Gross; Arthur W English
Journal:  J Neurosci Res       Date:  2017-08-03       Impact factor: 4.164

2.  Luminopsins integrate opto- and chemogenetics by using physical and biological light sources for opsin activation.

Authors:  Ken Berglund; Kara Clissold; Haofang E Li; Lei Wen; Sung Young Park; Jan Gleixner; Marguerita E Klein; Dongye Lu; Joseph W Barter; Mark A Rossi; George J Augustine; Henry H Yin; Ute Hochgeschwender
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-05       Impact factor: 11.205

3.  Removable cranial windows for long-term imaging in awake mice.

Authors:  Glenn J Goldey; Demetris K Roumis; Lindsey L Glickfeld; Aaron M Kerlin; R Clay Reid; Vincent Bonin; Dorothy P Schafer; Mark L Andermann
Journal:  Nat Protoc       Date:  2014-10-02       Impact factor: 13.491

4.  Chemically activated luminopsins allow optogenetic inhibition of distributed nodes in an epileptic network for non-invasive and multi-site suppression of seizure activity.

Authors:  Jack K Tung; Fu Hung Shiu; Kevin Ding; Robert E Gross
Journal:  Neurobiol Dis       Date:  2017-09-18       Impact factor: 5.996

5.  Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model.

Authors:  Jessica R Zenchak; Brandon Palmateer; Nicolai Dorka; Tariq M Brown; Lina-Marie Wagner; William E Medendorp; Eric D Petersen; Mansi Prakash; Ute Hochgeschwender
Journal:  J Neurosci Res       Date:  2018-03-25       Impact factor: 4.164

6.  Step-function luminopsins for bimodal prolonged neuromodulation.

Authors:  Ken Berglund; Alejandra M Fernandez; Claire-Anne N Gutekunst; Ute Hochgeschwender; Robert E Gross
Journal:  J Neurosci Res       Date:  2019-04-07       Impact factor: 4.164

7.  Optochemogenetic Stimulation of Transplanted iPS-NPCs Enhances Neuronal Repair and Functional Recovery after Ischemic Stroke.

Authors:  Shan Ping Yu; Jack K Tung; Zheng Z Wei; Dongdong Chen; Ken Berglund; Weiwei Zhong; James Y Zhang; Xiaohuan Gu; Mingke Song; Robert E Gross; Shinn Z Lin; Ling Wei
Journal:  J Neurosci       Date:  2019-07-01       Impact factor: 6.167

8.  Selective postnatal excitation of neocortical pyramidal neurons results in distinctive behavioral and circuit deficits in adulthood.

Authors:  William E Medendorp; Andreas Bjorefeldt; Emmanuel L Crespo; Mansi Prakash; Akash Pal; Madison L Waddell; Christopher I Moore; Ute Hochgeschwender
Journal:  iScience       Date:  2021-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.